期刊文献+

载穿心莲内酯的氨基修饰介孔二氧化硅纳米粒的制备及其初步药效学评价 被引量:2

Preparation and Preliminary Pharmacodynamic Evaluation of Amino-modified Mesoporous Silica Nanoparticles Loaded with Andrographolide
原文传递
导出
摘要 采用3种方法制备了氨基修饰的介孔二氧化硅纳米粒(NH2-MSN),对其形貌和结构进行表征。选用其中1种具有较大的比表面积(1 227.4 m2/g)和孔容积(0.67 m3/g)、介孔形状规则且孔径均一的NH2-MSN(称为M3)。该制品的平均粒径为(148.1±3.1)nm,?电位为(37.04±0.22)m V。用其与穿心莲内酯照1∶1的质量比投料制备纳米粒,结果载药量及包封率为(41.7±2.3)%和(80.7±4.7)%。建立了二甲苯致小鼠耳肿胀模型,初步评价该载药纳米粒的药效。结果表明,与穿心莲内酯混悬液及市售片剂相比,该载药纳米粒的抗炎作用较优。 The amino-modified mesoporous silica nanoparticles (NH2-MSN) were prepared by three methods, and their morphologies and structures were characterized. One of the prepared NH2-MSN, named as M3, with large specific surface area of 1 227.4 m^2/g, pore volume of 0.67 m^3/g, uniform size and oriented well-defined mesopores was selected. The average particle size and ζ potential of M3 were (148.1±3.1)nm and (37.04±0.22)mV. The drug loading and entrapment efficiency of andrographolide in the product prepared with M3 and andrographolide in the feed ratio of 1 : 1 were (41.7±2.3) % and (80.7±4.7) %. The pharmacodynamics of the product was preliminary investigated with the xylene-induced mouse ear edema model. The results showed that the anti-inflammatory effect of the product was superior to those of andrographolide suspensions and commercially available tablets.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2015年第11期1186-1191,共6页 Chinese Journal of Pharmaceuticals
基金 陕西省重点科技创新团队计划项目(2012KCT-18)
关键词 穿心莲内酯 氨基修饰 介孔二氧化硅纳米粒 制备 表征 药效学评价 andrographolide amino-modified mesoporous silica nanoparticle preparation characterization pharmacodynamic evaluation
  • 相关文献

参考文献12

  • 1刘意,龙晓英,何琳,曾桂先,林雁,李婷,胡宗科.穿心莲内酯微乳的制备及含量测定[J].中成药,2010,32(8):1424-1426. 被引量:13
  • 2Cheung MT, Ramalingam R, Lau KK, et al.Cell typedependent effects of andrographolide on human cancer celllines[J].Life Sci, 2012, 91(15-16): 751-760.
  • 3吕巧莉,涂国刚,王嘉琦,李少华.穿心莲内酯的研究进展及临床应用[J].南昌大学学报(医学版),2013,53(1):83-86. 被引量:56
  • 4Mamaeva V, Sahlgren C, Lindén M.Mesoporous silicananoparticles in medicine—Recent advances[J].Adv DrugDeliv Rev, 2013, 65(5): 689-702.
  • 5Shen J, Song G, An M, et al.The use of hollow mesoporoussilica nanospheres to encapsulate bortezomib and improveefficacy for non-small cell lung cancer therapy[J] .Biomaterials, 2014, 35(1): 316-326.
  • 6St?be r W, Fink A, Bohn E.Cont rol l ed growth ofmonodisperse silica spheres in the micron size range[J].JColloid Interf Sci, 1968, 26(1): 62-69.
  • 7M?ller K, Kobler J, Bein T.Colloidal suspensions ofnanometer-sized mesoporous silica[J].Adv Funct Mater,2007, 17(4): 605-612.
  • 8Bhattacharyya S, Wang H, Ducheyne P.Polymer-coatedmesoporous silica nanoparticles for the controlled release ofmacromolecules[J].Acta Biomater, 2012, 8(9): 3429-3435.
  • 9Kruk M, Jaroniec M.Gas adsorption characterization ofordered organic?inorganic nanocomposite materials[J].Chem Mater, 2001, 13(10): 3169-3183.
  • 10Ozeki T, Tagami T.Functionally engineered nanosizedparticles in pharmaceutics: improved oral delivery of poorlywater-soluble drugs[J].Curr Pharm Des, 2013, 19(35):6259-6269.

二级参考文献35

共引文献64

同被引文献57

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部